MedTrace Logo

Fractionated Carbon Dioxide Laser Therapy for Treatment of Peyronie's Disease

NCT04326465 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2024-06-04

No results posted yet for this study

Summary

This is a pilot study that evaluates the use of Fractional Carbon Dioxide Laser Therapy in the treatment of Peyronie's Disease. Study participants will be assigned to receive Fractional Carbon Dioxide Laser Therapy at 10-15% laser density coverage.

Conditions

  • Peyronies Disease

Interventions

DEVICE

Fractional Carbon Dioxide Laser Therapy at 10-15% Laser Density Coverage

Fractional Carbon Dioxide Laser Therapy is an ablative therapy where abnormal collagen in scarred tissue is destroyed to permit the formation of more organized collagen. Previous studies have demonstrated its efficacy in treating medical conditions (ex. hypertrophic scars) similar to Peyronies Disease. There is evidence that Fractional Carbon Dioxide Laser Therapy has the ability to target and alter the molecular pathways that are similar to the ones that lead to Peyronie's Disease.

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Ryan Flannigan, MD · UBC Faculty of Medicine - Department of Urologic Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2023-12-31
Completion
2023-12-31
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04326465 on ClinicalTrials.gov